Researchers led by Bernard Vanove of OSE Immunotherapeutics report in the December 7, 2016 issue of the Journal of Immunology on the first-in-human study of FR1041. OSE and collaborators at the University of Nantes and Janssen conducted a detailed phase I evaluation of safety, pharmacokinetics, pharmacodynamics and potency of FR104 in healthy volunteers.
Novel nonglycemic biomarker for metformin
The Outcome Reduction with Initial Glargine Intervention (ORIGIN) trial delivers more insight on biomarkers that have potential to help treat patients with dysglycemia.1 Hertzel C. Gerstein and colleagues report Growth Differentiation Factor 15 as a novel biomarker for the use and dosing of metformin, in a study published in Diabetes Care last month.
Social status can be used as predictor of life expectancy and overall health. It is easy to conclude that this is a result of better diet, healthcare, and lack of external risk factors but, as a team of researchers reported in the November 25th issue of the journal Science, movement in social status in rhesus macaques influenced changes in immune system phenotypes.